{"id":543139,"date":"2021-05-13T13:54:01","date_gmt":"2021-05-13T13:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543139"},"modified":"2021-05-13T13:54:01","modified_gmt":"2021-05-13T13:54:01","slug":"chronic-wounds-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-wounds-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_543139.html","title":{"rendered":"Chronic Wounds Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Chronic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cChronic Wounds \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Chronic Wounds – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

DelveInsight’s “Chronic Wounds – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the  Chronic Wounds, historical and forecasted epidemiology as well as the  Chronic Wounds market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The total incident population of chronic wounds in the G8 was observed to be 26,621,142 in 2017.  <\/p>\n<\/li>\n

  2. \n

    DelveInsight’s estimates show a higher incidence of chronic wounds in China with an estimated number of 15,317,053 cases in 2017 followed by the United States, with an estimated 6,549,447 cases in 2017.  <\/p>\n<\/li>\n

  3. \n

    Among the EU-5 countries, Germany had the highest incident population of chronic wounds with 909,985 cases, followed by France and Italy. On the other hand, Spain had the lowest incident population of 317,367 in 2017. <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Chronic Wounds market report covers a descriptive overview and comprehensive insight of the Chronic Wounds epidemiology and Chronic Wounds market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Chronic Wounds market report provides insights on the current and emerging therapies.<\/p>\n

    3. Chronic Wounds market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Chronic Wounds market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Wounds market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/chronic-wounds-market-report<\/span><\/a><\/strong><\/p>\n

    Chronic Wounds: Overview<\/strong><\/p>\n

    A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do; wounds that do not heal within three months are often considered chronic.<\/p>\n

    The key player involved in the Chronic Wounds market:<\/p>\n

      \n
    1. \n

       Anterogen, <\/p>\n<\/li>\n

    2. \n

      ViroMed BioPharma, <\/p>\n<\/li>\n

    3. \n

      Novalead Pharma, <\/p>\n<\/li>\n

    4. \n

      Oneness Biotech, <\/p>\n<\/li>\n

    5. \n

      MediWound, <\/p>\n<\/li>\n

    6. \n

      Tissue Tech\/Amniox Medical,<\/p>\n<\/li>\n

    7. \n

      Charsire Biotechnology, <\/p>\n<\/li>\n

    8. \n

      Energenesis Biomedical,<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Chronic Wounds treatment<\/a> scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

         ALLO-ASC-DFU<\/p>\n<\/li>\n

      2. \n

        Engensis<\/p>\n<\/li>\n

      3. \n

        Galnobax<\/p>\n<\/li>\n

      4. \n

        ON101<\/p>\n<\/li>\n

      5. \n

        EscharEx<\/p>\n<\/li>\n

      6. \n

        TTAX01<\/p>\n<\/li>\n

      7. \n

        CSTC1<\/p>\n<\/li>\n

      8. \n

        . ENERGI-F703<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/chronic-wounds-market-report<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Chronic Wounds Patient Share (%) Overview at a Glance<\/p>\n

        5. Chronic Wounds Market Overview at a Glance<\/p>\n

        6. Chronic Wounds Disease Background and Overview<\/p>\n

        7. Chronic Wounds Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Chronic Wounds<\/p>\n

        9. Chronic Wounds Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Chronic Wounds Emerging Therapies<\/p>\n

        12. Chronic Wounds Market Outlook<\/p>\n

        13. Country-Wise Chronic Wounds Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Chronic Wounds Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Chronic Wounds- Pipeline Insights, 2021<\/strong><\/p>\n

        “Chronic Wounds Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Chronic Wounds market. A detailed picture of the  Chronic Wounds pipeline landscape is provided, which includes the disease overview and  Chronic Wounds treatment guidelines.<\/p>\n

        Chronic Wounds – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Chronic Wounds – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Wounds epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cChronic Wounds \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-543139","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543139"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}